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ABSTRACT Most genome-wide association studies to date have been performed in populations of
European descent, but there is increasing interest in expanding these studies to other populations. The
performance of genotyping chips in Asian populations is not well established. Therefore, we sought to test
the performance of widely used ﬁxed-marker, genome-wide association studies chips in the Han Chinese
population. Non-HapMap Chinese samples (n = 396) were genotyped using the Illumina OmniExpress and
Affymetrix 6.0 platforms, whereas a subset also were genotyped using the Immunochip. Genotyped
markers from the Affymetrix 6.0 and Illumina OmniExpress were used for full genome imputation based on
the HapMap 2 JPT+CHB (Japanese from Tokyo, Japan and Chinese from Beijing, China) reference panel.
The concordance between markers genotypes for the three platforms was very high whether directly
genotyped or genotyped and imputed single nucleotide polymorphisms (SNPs; .99.8% for directly gen-
otyped and .99.5% for genotyped and imputed SNPs, respectively) were compared. The OmniExpress
chip data enabled more SNPs to be imputed, particularly SNPs with minor allele frequency .5%. The
OmniExpress chip achieved better coverage of HapMap SNPs than the Affymetrix 6.0 chip (73.6% vs.
65.9%, respectively, for minor allele frequency .5%). The Affymetrix 6.0 and Illumina OmniExpress chip
have similar genotyping accuracy and provide similar accuracy of imputed SNPs. The OmniExpress chip
however provides better coverage of Asian HapMap SNPs, although its coverage of HapMap SNPs is
moderate.
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Genetic polymorphism is known to contribute to phenotypic variation,
disease risks, and an individual’s response to pharmaceuticals and the
environment. For the past 20 years, genetic linkage combined with
positional cloning has achieved tremendous success for mapping
the variations that underlie monogenic Mendelian diseases (Jimenez-
Sanchez et al. 2001). However, it was only with the development of the
genome-wide association study (GWAS) approach that signiﬁcant
progress was made mapping disease-associated loci in common com-
plex human diseases (Wang et al. 2007). Since the advent of the GWAS
era with the publication of the Wellcome Trust Case Control Consor-
tium studies in 2007 (The Wellcome Trust Case Control Consortium
2007), GWAS has become a routinely used tool to identify common,
low-risk variants associated with or causative of a wide variety of human
diseases. This has led to the robust identiﬁcation of more than 500 loci
associated with common human diseases, representing a huge leap in
our understanding of the aetiopathogenesis of human disease (Hindorff
et al. 2009; Manolio et al. 2009).
The GWAS approach has matured considerably since its in-
troduction. The key technical advances have come about through
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reﬁnement of single-nucleotide polymorphism (SNP) selection on
chips, marked increases in SNP density, the development of copy
number variant tagging approaches, and improvements in chip
throughput and reduction in per SNP genotyping costs. At the
moment, Illumina (http://www.illumina.com) and Affymetrix (http://
www.affymetrix.com) microarrays are the two most popular micro-
array platforms in the GWAS research area. The ability to identify
associations depends heavily on the coverage of the genotyping chip
used (Barrett and Cardon 2006). This coverage varies signiﬁcantly
between major ethnic groups and can be assessed in silico using pre-
viously genotyped samples of known ethnicity, typically from the
HapMap study (Barrett and Cardon 2006; The International Hapmap
Consortium 2005; Pei et al. 2008). This approach does not take into
account real-world factors, notably the genotyping success rate of the
different platforms and chips.
To date, most GWAS studies have been performed in populations
of European descent. Interest in gene-mapping in Asian and African
populations in particular has increased recently, driven at least partly
by the fact that the so-called “low-hanging fruit” already have been
identiﬁed for most common human diseases and the increasing evi-
dence of speciﬁcity of a signiﬁcant number of genetic associations to
individual ethnic groups (e.g., Cai et al. 2011; Carty et al. 2011; Noguchi
et al. 2011; Smith et al. 2011; Yoon et al. 2012). This is particularly
the case in East Asia, where large case collections have already been
established, or where high-quality health services in large popula-
tions enable the establishment of suitable case collections for GWAS
studies. Transethnic mapping, or comparing association ﬁndings in
ethnically remote populations, can be highly informative about
established loci in addition to identifying novel loci (Hughes et al.
2011). When disease associations are shared (with the same poly-
morphisms) between ethnically remote groups, this implies that the
same causal variant is in linkage disequilibrium with the genotyped
variant in each population, indicating a common founder mutation
(Franceschini et al. 2012; Twee-Hee Ong et al. 2012).
Here, we test the coverage of two commonly used genotyping
chips, the Affymetrix SNP Array 6.0 (abbreviated as Affymetrix 6.0)
and Illumina Human OmniExpress Bead Chip (abbreviated as
OmniExpress), in a Han Chinese population (n = 396). The
Affymetrix 6.0 is designed to genotype more than 906,600 SNPs
and 946,000 copy number variants. The OmniExpress is an Illumina
Inﬁnium HD BeadChip, which is designed to genotype 733,202
markers per sample. A subset of individuals also was genotyped using
the Immunochip, an Illumina Inﬁnium chip containing 196,524
polymorphisms for known immunogenetic loci (Cortes and Brown
2011). Chip performance was assessed in relation to data quality and
genomic coverage, both for directly genotyped and imputed SNPs.
Genotype concordance was evaluated between the Affymetrix 6.0
and OmniExpress, as well as between these two platforms and a third
genotyping platform, the Immunochip.
MATERIALS AND METHODS
Study samples
This study was approved by the research ethics committee of the
Second Military Medical University, China. Blood samples were
obtained from patients attending outpatient clinics in Changzheng
Hospital, Shanghai, China. All the study subjects provided signed
informed consent. Subjects genotyped with the Affymetrix 6.0
platform were a subset of a larger cohort of non-HapMap Han
Chinese individuals at Changzheng Hospital, which included rheu-
matoid arthritis cases (n = 51) and controls (n = 188). Only control
subjects were genotyped further using OmniExpress or Immunochip.
Genomic DNA was extracted from peripheral blood leukocytes using
the AxyPrep Blood Genomic DNA Miniprep Kit (Axygen, Union
City, CA) according to the manufacturer’s instructions. All genomic
DNA was resuspended in TE Buffer for the following study.
Genotyping
The concentration of genomic DNA was measured using the Quant-iT
PicoGreen dsDNA assay (Invitrogen, Carlsbad, CA), and concentra-
tions were standardized to 50 ng/mL for genotyping. All samples were
genotyped initially using the Illumina OmniExpress (Illumina Inc., San
Diego, CA) and Affymetrix 6.0 (Affymetrix Inc., Santa Clara, CA)
chips. Correlation of genotypes was then checked with a further Illu-
mina Inﬁnium chip, the Immunochip (Illumina Inc.), which contains
a mixture of common and rare variants (Cortes and Brown 2011). All
platforms were operated according to the manufacturer’s instructions.
Genotype clustering and quality control
Illumina genotype clustering was performed using Illumina’s Bead-
Studio software (Illumina Inc.). SNPs were reclustered using the
study samples, low quality subjects were removed, and a subset of
clustering results were manually inspected and veriﬁed. All SNPs with
GenCall scores less than 0.15 were excluded. For Affymetrix chips,
clustering was performed using the program Birdseed version 2, as
implemented using Affymetrix Genotyper Console v4.0 (Affymetrix
Inc.), using the default quality control (QC) thresholds. Population
stratiﬁcation was assessed with Eigenstrat and SmartPCA (both avail-
able from http://genepath.med.harvard.edu/~reich/Software.htm) us-
ing the HapMap phase 3 Release 27 data (Price et al. 2006). This
identiﬁed three ethnic outliers, which were removed before further
analysis. Genotyped SNPs were evaluated using PLINK version 1.07
(pngu.mgh.harvard.edu/purcell/plink/), and markers with call rates
less than 95%, minor allele frequency (MAF) less than 1%, and Hardy-
Weinberg Equilibrium P-values less than 1026 as were excluded from
further analysis (Purcell et al. 2007). Genotyping data in PLINK for-
mat has been deposited at the European Genome Phenome Archive
(EGA, Genome-Phenome http://www.ebi.ac.uk/ega/) which is hosted
at the European Bionformatics Institute, under accession number
EGAS00000000131.
Imputation
Imputations were carried out using MACH (www.sph.umich.edu/csg/
abecasis/MACH) with 50 rounds of model building (Li et al. 2010).
Figure 1 Study sample size. The total number of individuals geno-
typed by each platform is indicated under the platform name. Sample
sizes in overlap regions represent the number of study subjects
genotyped by two or more platforms.
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The phase 2 JPT+CHB (Japanese from Tokyo, Japan and Chinese
from Beijing, China) HapMap Release 27 data were used as the ref-
erence panel. Imputation quality was assessed using the R2 metric.
Imputed SNPs with R2 less than 0.3 were considered to be of poor
quality and were excluded from analysis of imputation efﬁcacy and
genotyping concordance. MACH output ﬁles were converted to
PLINK format using the free software GenGen [www.openbioinfor-
matics.org/gengen/ (Wang et al. 2007)]. Coverage was calculated as
the number of genotyped plus imputed SNPs (r2. 0.8) divided by the
number of genotyped HapMap markers for the JPT+CHB reference
panel at a given MAF. Corrected coverage was calculated using the
formula presented in Barrett and Cardon (2006), which adjusts cov-
erage estimates for the total number of polymorphisms in the genome.
Concordance analysis
Genotype concordance was analyzed using PLINK version 1.07 with
the merge function in merge-mode 7, which compares concordance
ignoring missing genotypes (Purcell et al. 2007). Prior to comparison
SNPs genotyped on different platforms were adjusted for strand differ-
ences and allele coding to allow for accurate assessment of homozygote
to homozygote miscalls as discussed in Results. Figure 1 shows the
number of individuals genotyped by each pair of platforms, and Table
1 shows the number of shared markers. Types of discordance, MAF,
and R2 values for each SNP were extracted from PLINK and GenGen
ﬁles using Perl scripts. Correlations between concordance, MAF, R2
were analyzed using the R function cor.test, and scatterplots were made
using the R plot function (R Development Core Team 2005).
RESULTS
Genotyping success and concordance across chips
A total of 396 subjects were genotyped, with subsets subjects
genotyped on one, two, or all three platforms (Figure 1). For each
array type, data were ﬁrst subjected to QC to remove SNPs with low
call rates and MAF less than 1%. For the Affymetrix 6.0 array, 582,284
SNPs (62.28% of total markers) passed QC and had MAF greater than
1% for each array. The number of SNPs that were successfully geno-
typed by the OmniExpress chip was 593,582 (81.19% of total
markers), which was slightly greater than for Affymetrix 6.0. For
the Immunochip, 82,084 markers had MAF less than 0.01, and an
additional 2,388 failed QC, leaving 112,112 (57.04% of total markers)
genotyped markers. Genotype concordance between chip types was
very high for all pairs of platforms; dually genotyped SNPs were more
than 99.8% concordant in all cases (Table 1). No signiﬁcant differ-
ences were noted between pairwise concordance, indicating that for
genotypes that passed QC, genotyping accuracy did not vary substan-
tially between the different platforms.
Imputation efﬁcacy
Information on imputation efﬁcacy for HapMap SNPs using genotyped
Affymetrix 6.0 and OmniExpress markers is presented in Table S1. The
number of imputable SNPs refers to the number of SNPs in the
HapMap II CHB+JPT data set for a particular chromosome (Table
S1A and B, second column). Imputation efﬁcacy was initially eval-
uated using the MACH default value of r2 =0.3 as in Nothnagel et al.
(2009). Overall, imputations were more efﬁcacious using the
OmniExpress chip, with 4.59% of SNPs failing QC vs. 7.10% for
the Affymetrix 6.0. For both data sets, there was a high prevalence
of SNPs with MAF less than 1%, but this was greater for the Affy-
metrix 6.0 chip (8.42%) than the OmniExpress (4.72%).
Coverage of HapMap SNPs
Imputed SNPs also were evaluated at r2 = 0.80 to calculate coverage of
HapMap CHB+JPT markers (Table 2). The HapMap Phase II CHB
+JPT panel contains 2,133,507 markers with MAF greater than 5%.
Using the OmniExpress platform, 25.3% of these were genotyped,
whereas 52.9% were successfully imputed, giving a naïve coverage rate
of 78.2%. Using Barrett and Cardon’s corrected formula for coverage
with an estimate of 7.5 million SNPs in the genome, we calculated
coverage as 73.0% (Barrett and Cardon 2006), which is much lower
than the 91% coverage for markers with MAF greater than 5%
reported by Illumina for JPT+CHB populations (www.illumina.com/
products/human_omni_express.ilmn). Corresponding coverage esti-
mates for HapMap SNPs with MAF greater than 1% were 76.1%
(uncorrected) and 71.1% (corrected; Table 2). Using the Affymetrix
platform, we found that the empirical coverages for SNPs with MAF
greater than 5% were 66.6% (uncorrected) and 59.2% (corrected), and
for MAF greater than 1% were 66.4% (uncorrected) and 57.3% (cor-
rected). This observed coverage was much lower than the theoretical
coverage of 84% for JPT+CHB reported in Li et al. (2008).
Concordance of imputed SNPs
The number of imputable SNPs, i.e., the number of SNPs for one
platform that can be imputed using a second platform, was calculated
as the number of unshared (not dually genotyped) markers with phas-
ing information in the HapMap II CHB+JPT set (Table 3). Imputation
efﬁcacy between platforms corresponds to the percentage of imputable
SNPs which passed imputation QC (r2 . 0.3, MAF . 0.1, call rate .
0.95; Table 4). The OmniExpress platform was more successful at
imputing Affymetrix 6.0 markers than vice versa; however, both plat-
forms had similar efﬁcacy for imputation of Immunochip SNPs.
Concordance between imputed and genotyped SNPs for pairs of
array platforms was very similar to concordance between pairs of
genotyped SNPs (Table 1 and Table 4). Concordance rates exceeded
99.5% in all cases, and no differences were noted in the concordance
rates for different pairs of genotyping arrays. This ﬁnding suggests
that imputation is sufﬁciently robust to permit combining imputed
and genotyped SNPs in studies using both Affymetrix 6.0 and
OmniExpress arrays.
Discordance between imputed and genotyped markers was
classiﬁed into three categories: (1) a heterozygote mis-called as
a homozygote, (2) a homozygote mis-called as a heterozygote, and
n Table 1 Concordance between genotyped SNPs
Array 1 Array 2
No. Shared Genotyped SNPs
Passing QC with MAF . 0.01 Percent Concordance
Affymetrix 6.0 OmniExpress 146,885 99.89
Affymetrix 6.0 Immunochip 13,644 99.89
OmniExpress Immunochip 18,859 99.97
The third column indicates the number of SNPs shared by Array 1 and Array 2 after quality and MAF ﬁltering. Concordance rates presented
in the fourth column represent the sum of counts of concordant markers for each subject divided by the total number of markers for all
subjects. MAF, minimum allele frequency; SNP, single-nucleotide polymorphism.
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(3) a homozygote called as the opposite homozygote. For all chip
types, homozygote mis-calls as heterozygotes were more common
than the converse (Table 4). Homozygote-to-homozygote mis-calls
were uncommon with all chip types, comprising less than 5% of
miscalls in all cases, and occurred slightly less frequently in the
imputed OmniExpress data than the imputed Affymetrix 6.0 data
(Table 4). Interestingly, homozygote mis-calls were noted between
the Illumina OmniExpress and Immunochip arrays, which use the
same strand designation system (Table 4).
Correlation between concordance, MAF, and R2
Concordance was analyzed on a per-marker basis to explore
correlations with MAF and R2, as well as to determine the types of
discordance present. It has been previously reported that imputation
accuracy is positively correlated with MAF, which implies that con-
cordance between genotyped and imputed markers also should in-
crease with increasing MAF (Pei et al. 2008; Marchini and Howie
2010). Here, we observed small but statistically signiﬁcant positive
correlations between MAF and concordance. A statistically signiﬁcant
but negligible correlation was observed between concordance and
both MAF (Pearson’s r = 0.07, P , 0.001) and R2 (r = 20.09, P ,
0.001) were detected when comparing the imputed OmniExpress
SNPs to the Affymetrix 6.0 genotyped SNPs (Figure 2, top panels).
Similarly, a negligible correlation was observed between concordance
and MAF (r = 20.04, P , 0.001) for the imputed Affymetrix 6.0
markers compared with OmniExpress genotypes (Figure 2, bottom
panels). The correlation between R2 and concordance was greater
(r = 20.12, P , 0.001), but still quite low.
DISCUSSION
In this study we have compared the real-world performance of two
widely used genotyping platforms, Affymetrix 6.0 and Illumina
OmniExpress, in a non-HapMap Han Chinese population. Concor-
dance between genotyped markers across the Affymetrix and Illumina
platforms, including the Immunochip, was high, with no signiﬁcant
differences noted between different pairs of chips. Nothnagel et al.
showed similarly high rates of concordance between the Affymetrix
6.0 and Illumina 550k platforms for genotyping in a German popu-
lation (Nothnagel et al. 2009). Concordance of imputed with directly
genotyped SNPs was slightly lower than between genotyped SNPs
alone, but the level of discordance was still quite low. Although this
discordance is minor, care must be taken when combining informa-
tion from different genotyping platforms for cases and controls be-
cause platform-speciﬁc differences can lead to spurious or inﬂated
associations (Sinnott and Kraft 2011). Low MAF had little practical
impact on the concordance or imputation quality as assessed by R2,
suggesting that these GWAS chips, although not speciﬁcally designed
to capture rare variants, may actually capture a signiﬁcant fraction of
genetic variation due to low frequency variants.
Although discordance between both directly genotyped and
imputed and genotyped SNPs was low, we noted differences in the
type of discordance, with a greater frequency of homozygote genotypes
being imputed as heterozygotes than the converse. A slightly greater
error rate was observed when comparing imputed data from Affymetrix
6.0 chips with either the OmniExpress or Immunochip data, than with
genotypes imputed from OmniExpress compared with directly geno-
typed Affymetrix 6.0 or Immunochip SNPs. This ﬁnding suggests that
the imputation accuracy from Affymetrix SNPs is lower than from
OmniExpress, although the difference was small. Imputation accuracy
was lower on average for Affymetrix platforms as compared to
Illumina platforms for CHB+JPT populations in a previous study by
Li et al. (2008).
Signiﬁcant differences were noted in the ability to impute from the
OmniExpress and Affymetrix 6.0, and imputation efﬁcacy using
n Table 2 Coverage of JPT+CHB HapMap 2 SNPs
No. JPT+CHB
HapMap SNPs
HapMap SNPs
Genotyped
HapMap SNPs
Imputed with r2 . 0.8 Coverage
Corrected
Coverage
MAF . 0.05
OmniExpress 2,133,507 540,163 (25.3%) 1,128,626 (52.9%) 78.2% 73.0%
Affymetrix 6.0 2,133,507 501,993 (23.5%) 919,764 (43.1%) 66.6% 59.2%
MAF . 0.01
OmniExpress 2,344,748 581,788 (24.8%) 1,288,127 (54.9%) 79.7% 71.1%
Affymetrix 6.0 2,344,748 512,669 (21.9%) 1,045,048 (44.6%) 66.5% 57.3%
Only SNPs with a genotyping rate greater than 0.95 were considered. Coverage was calculated as the number of genotyped plus imputed
SNPs (r2 . 0.8) divided by the number of genotyped HapMap markers for the JPT+CHB reference panel at a given MAF. Corrected
coverage was calculated using the formula presented in Barrett and Cardon (2006), which adjusts coverage estimates for the total number of
polymorphisms in the genome. MAF, minimum allele frequency; SNP, single-nucleotide polymorphism.
n Table 3 Imputable SNPs for each array
Array 1 Array 2
No. SNPs Passing QC with
MAF . 0.01 Genotyped on
Array 1 Only
No. Imputable SNPs Using HapMap
CHB+JPT Reference Set (Percent)
Affymetrix 6.0 OmniExpress 435,399 372,433 (85.53%)
OmniExpress Affymetrix 6.0 446,697 391,758 (87.70%)
Immunochip Affymetrix 6.0 28,305 25,844 (91.31%)
Immunochip OmniExpress 23,370 20,135 (86.16%)
To calculate the number of imputable SNPs, SNPs dually genotyped by two arrays were ﬁrst removed from consideration, as well as any
SNPs failing QC. The number of remaining markers with phasing information in the HapMap CHB+JPT set (the reference set for imputations)
was then tabulated. The percentages in the fourth column are the number of SNPs with phasing information divided by the number of non-
shared SNPs (third column). MAF, minimum allele frequency; QC, quality control; SNP, single-nucleotide polymorphism.
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MACH was much lower in general than previously reported [16].
Many imputed SNPs were not considered for further analysis due to
low genotyping rates, poor QC values, and MAF less than 1% in the
target panel (Table 2). Xu et al. (2009) demonstrated the presence of
signiﬁcant substructure in Han Chinese populations, with notable
differences between Northern and Southern Han subpopulations.
The HapMap CHB+JPT reference panel includes genotypes from
Northern Han (Beijing) and Japanese individuals, while our study
population was from Shanghai, which is in the Southern Han region.
Some markers which are polymorphic in the JPT+CHB reference panel
with MAF greater than 1% may be less polymorphic or monomorphic
in the Han Chinese population studied here, contributing to the reduced
imputation efﬁcacy. Greater imputation efﬁcacy might be achieved by
the use of mixed reference panels as described in Huang et al. (2009).
Using HapMap data, Illumina reports that OmniExpress chips
capture around 91% SNPs with MAF . 5% and r2 . 0.8 in CEU
(Utah residents with European ancestry from the Centre du Etude
Polymorphisme Humain collection) populations, with similarly good
n Table 4 Concordance and types of discordance in dually genotyped or genotyped and imputed SNPs
Platform 1 Platform 2
Concordance
(No. SNPs)
Homozygote to
Homozygote
Heterozygote to
Homozygote
Homozygote to
Heterozygote
Affymetrix 6.0 OmniExpress 99.89% (146,885) 45 (0.2%) 12486 (64.8%) 6750 (35.0%)
Affymetrix 6.0 OmniExpress Imputed 99.55% (252,679) 388 (0.3%) 55336 (44.1%) 69891 (55.6%)
Affymetrix 6.0 Immunochip 99.89% (13,644) 35 (3.9%) 466 (51.5%) 403 (44.6%)
OmniExpress Affymetrix 6.0 Imputed 99.52% (190,555) 853 (0.3%) 55336 (44.1%) 69891 (55.6%)
OmniExpress Immunochip 99.97% (18,859) 7 (0.8%) 343 (39.2%) 524 (60.0%)
Immunochip Affymetrix 6.0 Imputed 99.66% (19,727) 73 (2.2%) 1551 (45.7%) 1769 (52.1%)
Immunochip OmniExpress Imputed 99.77% (15,024) 186 (1.4%) 6056 (47.6%) 6492 (51.0%)
The number of SNPs exhibiting heterozygote to homozygote mismatch vs. homozygote mis-calls are indicated. Percentages indicate the percent of discordant calls
which fall into each category. SNP, single-nucleotide polymorphism.
Figure 2 Concordance vs. MAF and R2 for genotyping platforms. Each data point represents a genetic marker genotyped on one platform and
imputed by the other. Concordance represents the proportion of subjects for which the directly obtained and imputed genotypes were the same,
and MAF and R2 were calculated using PLINK.
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performance also in CHB+JPT (91% in HapMap). In our study, cov-
erage was much lower for the OmniExpress platform (Table 3). This
decreased coverage was largely attributable to imputation efﬁcacy as
described previously. Coverage estimates are known to be inﬂated
when coverage is calculated using on the reference panel from which
tagSNPs were selected during the chip design process (Barrett and
Cardon 2006). This results in overﬁtting, which in combination with
the small sample size of the HapMap data set can lead to exaggerated
coverage estimates (Hao et al. 2008). Markers for the Illumina
OmniExpress platform were selected from HapMap SNPs represen-
tative of common variants (MAF . 5%) which may also resulted
in overestimation of coverage (www.illumina.com/products/human_
omni_express.ilmn). The use of more specialized reference panels with
larger sample sizes, and genotyping platforms tailored to East Asian
populations could improve coverage in future studies.
Coverage for the Affymetrix 6.0 chip was lower than for the
OmniExpress because a greater proportion of HapMap SNPs could be
imputed using OmniExpress. Lower coverage of CEU, JPT+CHB, and
YRI populations by Affymetrix arrays as compared with Illumina
arrays has previously been reported and may be related to differences
in SNP selection between the two platforms (Mägi et al. 2007; Li et al.
2008, 2010). The Affymetrix microarray technology relies on the dif-
ferential hybridization of genomic DNA to 25-mer probes which match
SNP alleles, while the Illumina Inﬁnium technology uses hybridization
followed by primer extension (Kennedy et al. 2003; Steemers et al.
2006; Ragoussis 2009). Although Illumina emphasizes tagging SNPs,
SNP selection for the Affymetrix system is limited by technical con-
straints. For example, SNPs chosen for the Affymetrix 6.0 assay must
be located within fragments generated by a restriction digest by the
enzymes Nsp I and Sty I (http://www.affymetrix.com), and are then
required to ameliorate to universal hybridization conditions for adaptor
ligation and subsequent inclusion on the array (Ding and Jin 2009).
This study demonstrates that, in a real-world setting, both the
Affymetrix 6.0 and OmniExpress chips achieve good coverage of
genetic variation in Japanese and Chinese as deﬁned by HapMap.
From our results, we can conclude that despite the different
mechanisms in chemistry, the Affymetrix 6.0 and OmniExpress
platforms both give good call rates and similar genotype accuracy,
in comparison with the Illumina Inﬁnium Immunochip genotypes.
Further, the imputation accuracy comparing SNPs imputed on one
platform with SNPs genotyped on another platform was high,
indicating that, with appropriate quality control, it is valid to combine
imputed and genotyped SNPs in studies where samples have been
genotyped either on the Affymetrix 6.0 or OmniExpress chips.
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